Wedbush Predicts Stronger Earnings for Viridian Therapeutics

Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Equities research analysts at Wedbush boosted their Q1 2025 earnings per share (EPS) estimates for Viridian Therapeutics in a report released on Thursday, February 27th. Wedbush analyst L. Chico now expects that the company will post earnings per share of ($1.01) for the quarter, up from their previous forecast of ($1.02). The consensus estimate for Viridian Therapeutics' current full-year earnings is ($4.03) per share. Wedbush also issued estimates for Viridian Therapeutics' Q2 2025 earnings at ($1.04) EPS, Q3 2025 earnings at ($0.98) EPS, Q4 2025 earnings at ($1.01) EPS, FY2025 earnings at ($4.03) EPS, FY2026 earnings at ($4.43) EPS and FY2029 earnings at $11.84 EPS.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.05) by $0.24. The business had revenue of $0.07 million for the quarter, compared to analysts' expectations of $0.05 million. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%.

VRDN has been the topic of several other research reports. HC Wainwright reiterated a "buy" rating and issued a $34.00 price target on shares of Viridian Therapeutics in a report on Monday, December 16th. Royal Bank of Canada increased their target price on Viridian Therapeutics from $44.00 to $47.00 and gave the company an "outperform" rating in a research note on Tuesday, December 17th. Needham & Company LLC reissued a "buy" rating and issued a $38.00 target price on shares of Viridian Therapeutics in a research note on Tuesday, January 7th. TD Cowen assumed coverage on Viridian Therapeutics in a research note on Monday, November 25th. They issued a "buy" rating on the stock. Finally, Wells Fargo & Company reissued an "equal weight" rating and issued a $27.00 target price (down previously from $37.00) on shares of Viridian Therapeutics in a research note on Thursday, December 19th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $35.70.

Remove Ads

Viridian Therapeutics Trading Up 3.9 %

Viridian Therapeutics stock traded up $0.60 during mid-day trading on Monday, hitting $15.88. The stock had a trading volume of 848,646 shares, compared to its average volume of 1,181,571. The stock has a 50-day simple moving average of $17.86 and a two-hundred day simple moving average of $19.64. The stock has a market capitalization of $1.26 billion, a PE ratio of -3.68 and a beta of 1.05. Viridian Therapeutics has a 12 month low of $11.40 and a 12 month high of $27.20. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.04.

Institutional Investors Weigh In On Viridian Therapeutics

A number of hedge funds have recently modified their holdings of the business. Voya Investment Management LLC raised its position in shares of Viridian Therapeutics by 5.1% during the fourth quarter. Voya Investment Management LLC now owns 21,397 shares of the company's stock worth $410,000 after purchasing an additional 1,038 shares during the period. Tudor Investment Corp ET AL raised its position in shares of Viridian Therapeutics by 3.0% during the fourth quarter. Tudor Investment Corp ET AL now owns 38,367 shares of the company's stock worth $735,000 after purchasing an additional 1,106 shares during the period. R Squared Ltd acquired a new stake in shares of Viridian Therapeutics during the fourth quarter worth about $26,000. Summit Investment Advisors Inc. raised its position in shares of Viridian Therapeutics by 24.7% during the fourth quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company's stock worth $147,000 after purchasing an additional 1,516 shares during the period. Finally, AlphaQuest LLC raised its position in Viridian Therapeutics by 119.0% in the 4th quarter. AlphaQuest LLC now owns 2,795 shares of the company's stock valued at $54,000 after buying an additional 1,519 shares during the last quarter.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.